使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Welcome to the HCA Healthcare third-quarter 2026 earnings conference call. Today's call is being recorded. (Operator Instructions)
歡迎參加 HCA Healthcare 2026 年第三季財報電話會議。今天的電話會議將被錄音。(接線員指示)
At this time, for opening remarks and introductions, I would like to turn the call over to Vice President of Investor Relations, Mr. Frank Morgan. Frank. Please go ahead, sir.
此刻,為了開場致詞與介紹,我想把電話交給投資人關係副總裁 Frank Morgan 先生。Frank。先生,請開始。
Frank Morgan - Vice President, Investor Relations
Frank Morgan - Vice President, Investor Relations
Good morning, and welcome to everyone on today's call. With me this morning is our CEO, Sam Hazen and our CFO, Mike Marks. Sam and Mike will provide some prepared remarks and then we'll take your questions.
各位早安,歡迎大家參加今天的電話會議。今天早上與我一同出席的有我們的執行長 Sam Hazen 與財務長 Mike Marks。Sam 與 Mike 將先做準備好的發言,接著我們會回答各位的提問。
Before I turn the call over to Sam, let me remind everyone that should today's call contain any forward-looking statements, they're based on management's current expectations. Numerous risks, uncertainties, and other factors may cause actual results to differ materially from those that might be expressed today. More information on forward-looking statements and these factors are listed in today's press release and in our various SEC filings.
在我把電話交給 Sam 之前,提醒各位,若今天的電話會議包含任何前瞻性陳述,皆係基於管理階層目前的預期。多項風險、不確定性及其他因素可能導致實際結果與今日所表達者有重大差異。關於前瞻性陳述及這些因素的更多資訊,已列於今日新聞稿以及我們向 SEC 提交的各項文件中。
On this morning's call, we may reference measures such as adjusted EBITDA, which is a non-GAAP financial measure. A table providing supplemental information on adjusted EBITDA and reconciling net income attributable to HCA Healthcare, Inc. Is included in today's release. This morning's call is being recorded, and a replay of the call will be available later today.
在今天早上的電話會議中,我們可能會提及如調整後 EBITDA 等指標,這是一項非 GAAP 財務衡量指標。提供調整後 EBITDA 補充資訊並將歸屬於 HCA Healthcare, Inc. 的淨利進行調節的表格,已包含在今日的新聞稿中。今天早上的電話會議將被錄音,稍晚也將提供重播。
With that, I'll now turn the call over to Sam.
那麼,我現在把電話交給 Sam。
Samuel Hazen - Chief Executive Officer, Director
Samuel Hazen - Chief Executive Officer, Director
Good morning.
各位早安。
Thank you for joining the call. The company's results in the third quarter reflected improvement in key areas of our business. First, demand for our services continued to grow at a solid rate.
感謝各位加入本次電話會議。公司第三季的結果反映出我們業務關鍵領域的改善。首先,我們服務的需求持續以穩健的速度成長。
Adjusted admissions on a same-facility basis grew 3% compared to 2.3% year-to-date.
以同院區(same-facility)基礎計算,調整後入院人次成長 3%,相較之下年初至今為 2.3%。
Inside this growth, insured volumes grew faster in the quarter than in the first half of the year.
在這項成長之中,第三季的投保量(insured volumes)成長速度快於上半年。
The third quarter reflected the 22nd consecutive quarter of volume growth for the company.
第三季是公司連續第 22 季的量能成長。
Second, revenue per adjusted admission for our insured business, excluding supplemental payments, increased at a higher rate than in the first half of the year. This increase partially offset the payer mix pressure from continued volume declines for patients who were formerly covered in health insurance exchanges and are now uninsured.
第二,我們投保業務(insured business)每調整後入院人次的收入(不含補充性給付)以高於上半年的速度增加。這項增加部分抵銷了付款方組合(payer mix)壓力;該壓力來自於先前在健康保險交易所投保、如今轉為無保險者的病患量能持續下滑。
Additionally, we had the modest incremental net benefit of $50 million in the quarter from Medicaid supplemental payment programs, primarily related to a recently approved Virginia program.
此外,本季我們從 Medicaid 補充性給付計畫獲得約 5,000 萬美元的溫和增量淨效益,主要與近期獲核准的維吉尼亞州計畫相關。
These factors coupled with improved cost results contributed to solid financial performance in the quarter that slightly exceeded our expectations.
這些因素再加上成本表現改善,促成了本季穩健的財務表現,且略高於我們的預期。
Diluted earnings per share as adjusted increased almost 4%. I've often mentioned that HCA has strong staying power because of our scale. The important role we play in providing critical services to communities and our disciplined culture.
調整後稀釋每股盈餘增加近 4%。我經常提到,HCA 之所以具備強大的持久力,是因為我們的規模、我們在為社區提供關鍵服務方面所扮演的重要角色,以及我們嚴謹的企業文化。
Despite the challenges this year brought about by federal policy changes, we have continued to move the company forward and believe we are positioned to end the year positively.
儘管今年因聯邦政策變動帶來挑戰,我們仍持續推動公司向前,並相信我們有條件以正向態勢結束今年。
As we look ahead to 2027, let me share a few preliminary observations around certain aspects of our business before we provide our full year guidance in January.
展望 2027 年,在我們於一月提供全年指引之前,我先就業務的若干面向分享一些初步觀察。
I'll remind everyone we are still early in our planning process and there are several important areas that remain fluid, including the policy environment.
提醒各位,我們仍處於規劃流程的早期階段,且仍有數個重要領域尚未定案,包括政策環境。
First.
第一。
We expect demand for services to remain strong with volume growth forecasted to be 2% to 3%. This range is consistent with our long-term thinking.
我們預期服務需求將維持強勁,並預估量能成長為 2% 至 3%。此區間與我們的長期看法一致。
Within the demand environment, we believe it's reasonable to assume for 2027 that fewer people will lose their coverage on the health insurance exchanges than we experienced in 2026.
在需求環境方面,我們認為對 2027 年而言,合理的假設是:相較於 2026 年,將會有較少的人在健康保險交易所失去保險保障。
However, we do expect that there still will be a meaningful impact on payer mix.
然而,我們確實預期付款方組合仍將受到顯著影響。
We need to get through the fourth quarter before we can provide more details.
我們需要先度過第四季,才能提供更多細節。
Next, we expect to receive approximately $550 million to $650 million less in Medicaid supplemental payment net benefits due to various state programs that received grandfather approvals in 2026 and reimbursed us for services we provided in prior years.
接著,我們預期 Medicaid 補充性給付的淨效益將減少約 5.5 億至 6.5 億美元,原因在於若干州的計畫於 2026 年獲得祖父條款(grandfather)核准,並就我們前幾年提供的服務對我們進行補償。
Last, we anticipate favorable cost performance, primarily due to our ongoing enterprise-wide resiliency program.
最後,我們預期成本表現將有利,主要來自我們持續推動的全企業韌性計畫(enterprise-wide resiliency program)。
And the operating leverage from the expected volume growth.
以及預期量能成長所帶來的營運槓桿。
When we aggregate the preliminary observations, we anticipate our earnings in 2027 will be generally consistent with 2026.
綜合這些初步觀察,我們預期 2027 年的獲利將大致與 2026 年一致。
Beyond 2027, we anticipate performance more in line with our long-term growth targets. This view makes three important assumptions: first, we move past the most significant effects on payer mix from the exchanges second, we assume no material policy changes beyond HR1.
在 2027 年之後,我們預期表現將更貼近我們的長期成長目標。此觀點建立在三項重要假設之上:第一,我們已度過交易所對付款方組合造成的最顯著影響;第二,我們假設除 HR1 之外不會有重大政策變動。
And finally, we have a set of strategic initiatives, including digital transformation, network development and ongoing resiliency programs that generate significant value.
最後,我們有一系列策略性計畫,包括數位轉型、網路發展,以及持續的韌性計畫,能創造顯著價值。
I'll reiterate, it is still early, but we believe these preliminary perspectives provide context for how we currently see the company's growth prospects.
我再重申一次,現在仍屬早期,但我們相信這些初步觀點可為各位提供脈絡,說明我們目前如何看待公司的成長前景。
Let me close with this: our colleagues continue to provide high-quality care to our patients and execute our strategic plans. I appreciate their efforts in delivering on our mission, and I want to thank them for their good work.
最後我想以這段話作結:我們的同仁持續為病患提供高品質照護,並落實我們的策略計畫。我感謝他們為實現我們使命所付出的努力,也要謝謝他們的辛勤工作。
As we get further into the execution of our plan, we believe it will enhance access for our patients with our capital spending, create a better work environment for our caregivers with our AI transformation initiatives and deliver value for our shareholders with our enterprise-wide resiliency program and balanced capital allocation.
隨著我們更深入執行計畫,我們相信這將透過資本支出提升病患就醫可近性;透過 AI 轉型計畫為照護人員打造更好的工作環境;並透過全企業韌性計畫與均衡的資本配置,為股東創造價值。
As we look to the future, I'm confident that HCA Healthcare has the right people, the right process and the financial position to achieve our long-term objectives.
展望未來,我有信心 HCA Healthcare 具備合適的人才、合適的流程,以及足以達成長期目標的財務狀況。
With that, I'll turn the call over to Mike for more details on the quarter.
接下來,我把電話交給 Mike,請他就本季提供更多細節。
Michael Marks - Chief Financial Officer, Executive Vice President
Michael Marks - Chief Financial Officer, Executive Vice President
Thank you, Sam, and good morning, everyone.
謝謝你,Sam,各位早安。
As Sam noted, demand for our services continued to grow at a solid rate. Compared to the prior year quarter, on the same-facility basis, admissions increased 2.7%, equivalent admissions increased 3%, and visits increased 5.1%.
如 Sam 所提到的,我們服務的需求持續以穩健的速度成長。與去年同期相比,以同院區基礎計算,入院人次增加 2.7%,等值入院人次(equivalent admissions)增加 3%,就診次數(visits)增加 5.1%。
Inpatient surgeries were down 1.4%. Outpatient surgeries were down 3.7%.
住院手術量下滑 1.4%。門診手術量下滑 3.7%。
Regarding surgical volumes, consistent with the second quarter, we continue to see solid growth in our emergent surgical volumes and pressure in elective.
就手術量而言,與第二季一致,我們持續看到急症手術量穩健成長,而選擇性手術(elective)則承受壓力。
Same facility equivalent admissions in our insured population, excluding exchanges, increased approximately 3% in the third quarter versus prior year.
在我們的投保族群中(不含交易所),同院區等值入院人次於第三季較去年同期增加約 3%。
Exchange equivalent admissions declined approximately 19% versus prior year quarter.
交易所等值入院人次較去年同期下滑約 19%。
For context, the third quarter of 2025 was our high watermark for exchange volume, making for a difficult comparison.
補充說明,2025 年第三季是我們交易所量能的高點,因此比較基期較為不利。
However, we did see sequential improvement in exchange volume from 2Q to 3Q of 2026 of approximately 8%. Like the second quarter, we continue to see patients who have lost coverage on the exchanges.
不過,我們確實看到 2026 年第 2 季到第 3 季的交易所投保量(exchange volume)按季改善約 8%。與第二季相同,我們仍持續看到在交易所失去保險保障的病患。
Migrate almost one-for-one to uninsured.
幾乎一比一地轉為無保險。
This one-for-one migration makes up approximately 80% of our uninsured volume growth, with the remaining 20% primarily related to a decrease in Medicaid conversions and mostly in Texas.
這種一比一的轉移約占我們無保險量成長的 80%,其餘 20% 主要與 Medicaid 轉換(conversion)下降有關,且多數發生在德州。
Our uninsured volume in third quarter 26 represented approximately 10.5% of total equivalent admissions versus 8.5% in the prior year quarter.
我們 2026 年第三季的無保險量約占總等值入院(equivalent admissions)的 10.5%,相較去年同期為 8.5%。
We estimate the payer mix shift from exchanges to uninsured resulted in an unfavorable impact on adjusted EBITDA of approximately $400 million in the quarter.
我們估計,付款方組合由交易所轉向無保險,對本季調整後 EBITDA 造成約 4 億美元的不利影響。
We now expect the full year unfavorable impact on adjusted EBITDA from payer mix shifts to be at or slightly above the upper end of the range of our previously updated estimates.
我們目前預期,全年因付款方組合變動對調整後 EBITDA 的不利影響,將落在或略高於我們先前更新估計區間的上緣。
For Medicaid supplemental payment programs, the company recognized approximately $50 million of incremental net benefit during the third quarter.
就 Medicaid 補充支付計畫(supplemental payment programs)而言,公司在第三季認列約 5,000 萬美元的增量淨效益。
We now expect the incremental net benefit for Medicaid supplemental payment programs to be between $600 million and $800 million for the full year 2026.
我們目前預期,2026 全年 Medicaid 補充支付計畫的增量淨效益將介於 6 億至 8 億美元。
This increase in our estimated range was driven equally by the grandfathered application from Virginia and one-time payments from across our other programs.
我們估計區間上調,主要同等來自維吉尼亞州既有(grandfathered)申請案,以及其他計畫的一次性付款。
We were pleased with our cost results in the quarter.
我們對本季的成本表現感到滿意。
Same facility cost per equivalent admission when excluding Medicaid supplemental payment programs was essentially flat versus prior year quarter, and it improved 40 basis points sequentially.
在排除 Medicaid 補充支付計畫後,同院所每等值入院成本與去年同期基本持平,且按季改善 40 個基點。
As we typically see an increase sequentially from second quarter to third quarter, this outcome reflects strong operating discipline from our teams.
由於我們通常會看到從第二季到第三季按季上升,這樣的結果反映出團隊強勁的營運紀律。
Moving to capital allocation and cash flow, capital expenditures totaled approximately $1.36 billion in the quarter.
接著談資本配置與現金流,本季資本支出合計約 13.6 億美元。
Additionally, we purchased approximately $3 billion of our outstanding shares and we paid $165 million in dividends for the quarter.
此外,我們回購了約 30 億美元的流通在外股份,並於本季支付 1.65 億美元股利。
Cash flow from operations was approximately $4.5 billion in the quarter.
本季營運活動現金流約 45 億美元。
Our debt to adjusted EBITDA leverage remains in the lower half of our stated target range, and we believe our balance sheet remains strong and well-positioned for the future.
我們的債務對調整後 EBITDA 槓桿比率仍位於既定目標區間的下半部,我們認為資產負債表依然穩健,且已為未來做好布局。
We currently expect to complete most of the existing authorized share repurchase program by year end, subject to market conditions and other factors.
在市場狀況及其他因素影響下,我們目前預期將於年底前完成現有已核准股票回購計畫的大部分。
As noted in our release, we are reaffirming our estimated guidance ranges for 2026.
如同我們在新聞稿中所述,我們重申 2026 年的指引區間估計。
Given our third quarter performance, we currently expect to be in the upper half of our guidance ranges for the year.
基於第三季表現,我們目前預期全年將落在指引區間的上半部。
I will now hand the call back to Frank Morgan for questions.
接下來我把電話交回給 Frank Morgan 進行問答。
Frank Morgan - Vice President, Investor Relations
Frank Morgan - Vice President, Investor Relations
Thank you, Mike. As a reminder, please limit yourself to one question so we might give as many as possible in the queue an opportunity to ask a question. Christine, you may now give instructions to those who would like to ask a question.
謝謝你,Mike。提醒各位,請每人限制一個問題,以便讓隊列中盡可能多的人有機會提問。Christine,請你現在向想提問的人說明操作方式。
Operator
Operator
(Operator Instructions) AJ Rice, UBS.
(接線員指示) AJ Rice,UBS。
AJ Rice - Analyst
AJ Rice - Analyst
Thanks. Hi everybody.
謝謝。各位好。
Maybe just, I know it's early to be given a lot of comments about 2027, and you're thinking about consistent EBITDA versus this year. It sounds like you're thinking there is a fairly substantial incremental public exchange headwind that you've got to overcome, and you're also talking about incremental savings from ongoing resiliency programs. I wonder if there's any way to flesh out sort of an order of magnitude of what you think that. Incremental public exchange headwind might be next year, even if it's a wide range? Similarly so, should we look for cost savings similar to the $400 million resiliency program you announced this year or next year?
我想問一下,我知道現在要對 2027 年做很多評論還太早,而你們也在思考 EBITDA 與今年持平。聽起來你們認為明年會有相當顯著的公共交易所(public exchange)逆風需要克服,同時也提到持續推動的韌性計畫(resiliency programs)將帶來額外節省。我想知道是否有辦法更具體說明一下你們對此的量級(order of magnitude)看法。明年的公共交易所增量逆風大概會是多少,即使是很寬的區間也可以?同樣地,我們是否應該期待成本節省會類似你們今年宣布的 4 億美元韌性計畫,或是明年也會有類似規模?
Michael Marks - Chief Financial Officer, Executive Vice President
Michael Marks - Chief Financial Officer, Executive Vice President
Well, AJ, I think what we try to do in preparing our early book comments is give you the best information we have at this point.
AJ,我想我們在準備年初初步展望評論時,會盡力提供目前掌握的最佳資訊。
As Sam noted in his prepared comments. We still are in the early stages of our planning cycle. And as we kind of finish fourth quarter, we're really studying two key components.
如同 Sam 在事先準備的發言中提到的。我們仍處於規劃週期的早期階段。而當我們接近完成第四季時,我們主要在研究兩個關鍵面向。
Number one is our results in the fourth quarter and how the strength of our core performance continues to mature.
第一是我們第四季的結果,以及核心表現的強勁程度如何持續成熟。
I think it's clear in third quarter, we were pleased with our core growth and we feel like we have momentum. We need to validate that in fourth quarter and that'll give us a really good sense.
我認為第三季很明顯,我們對核心成長感到滿意,也覺得有動能。我們需要在第四季驗證這點,這將讓我們有非常好的判斷依據。
Of our core growth as we kind of step into 2027.
來評估我們在邁入 2027 年時的核心成長。
The second thing that we've got to study is the exchange environment. And as we go through the fourth quarter first, we'll better information about how our exchange volumes perform here in the last quarter of the year. But we'll also have better intelligence about enrollment. The enrollment period starts on November 1st and it goes through mid-January. And so with those two things, we'll be in a much better positioned to give you our best sense of this on our January call, our fourth quarter call for '27 guidance.
第二件我們必須研究的是交易所環境。當我們先走完第四季,我們會有更完整的資訊,了解今年最後一季交易所投保量的表現。同時,我們也會對投保登記(enrollment)有更好的情報。投保期間從 11 月 1 日開始,持續到 1 月中旬。因此結合這兩點,我們在 1 月的電話會議、也就是第四季電話會議提供 2027 年指引時,將能以更好的狀態給出我們最好的判斷。
But I think as you think about core growth, you think about the headwinds that we have disclosed related to Medicaid state supplemental payment programs, and then what ends up happening with the exchanges in 2027. Those are the big moving parts, and we'll give you further guidance as we get on our fourth quarter call.
不過我認為,當你思考核心成長時,也要考量我們已揭露的、與 Medicaid 州級補充支付計畫相關的逆風,以及 2027 年交易所最終會如何發展。這些是主要的變動因素,我們會在第四季電話會議時提供進一步指引。
Samuel Hazen - Chief Executive Officer, Director
Samuel Hazen - Chief Executive Officer, Director
AJ, let me add to the cost. I mean, we see our resiliency agenda broadly as an ongoing strategic program for the company. We now have new capabilities. We have new technology. We're expanding our shared service platform as a result of that. And we're able to move the cost agenda.
AJ,我再補充一下成本部分。我的意思是,我們把韌性議程(resiliency agenda)廣義視為公司持續性的策略性計畫。我們現在具備新的能力。我們有新的技術。也因此正在擴大我們的共享服務平台。而我們能夠推動成本議程。
Systematically as a company today and heretofore we didn't have that ability because we didn't have the capabilities nor the technology and I think the mindset to accomplish it as a result of that. So when we started thinking about costs in 2027, as I mentioned in my.
以公司層面系統性地推進;而在此之前我們做不到,因為我們缺乏相關能力與技術,我也認為當時的思維模式不足以達成這件事。因此,當我們開始思考 2027 年的成本時,如同我在我的。
My comments, we do anticipate more value coming from our resiliency program broadly within our networks and from a cost standpoint overall for the company. And so that is more of a strategic agenda item that will carry itself into the future and be a part of our programmatic efforts as we move beyond 2027. I think the other point, Mike, is the Medicaid supplemental payment program is related to some payment. From prior year as we think about '27 also.
我的發言中提到,我們確實預期韌性計畫將在我們的網絡中廣泛帶來更多價值,並在公司整體成本面帶來效益。因此,這更像是一項策略性議程,會延續到未來,並成為我們在 2027 年之後持續推進的計畫性工作之一。我想另一點,Mike,是 Medicaid 補充支付計畫與某些付款有關。當我們也在思考 2027 年時,這些付款是來自前一年度。
Operator
Operator
Ann Hynes, Mizuho.
Ann Hynes,Mizuho。
Ann Hynes - Analyst
Ann Hynes - Analyst
Great.
太好了。
Thank you so much. I just want to ask about 340B. I know there is a regulation out there that if it goes into effect as is. Should benefit the for-profits that don't participate in that program.
非常感謝。我只是想問一下 340B。我知道外面有一項法規,如果按目前的樣子生效。應該會讓未參與該計畫的營利機構受益。
And I know that would probably be challenged at some point in the legal system, but does that that guidance assume any change in that program or any potential benefit? And if it does, have you sized that? Thanks.
我也知道那可能在某個時間點會在法律體系中受到挑戰,但那份指引是否假設該計畫會有任何變更或任何潛在利益?如果有的話,你們有量化過嗎?謝謝。
Michael Marks - Chief Financial Officer, Executive Vice President
Michael Marks - Chief Financial Officer, Executive Vice President
Thanks, Ann.
謝謝你,Ann。
So this is part of the Medicare OPPS rule that's proposed at this point.
所以這目前是 Medicare OPPS 規則中提出的內容之一。
We were pleased with the construct that is part of the proposed rule as it relates to a budget-neutral reallocation of 340B.
我們對於該提案規則中、與 340B 預算中立(budget-neutral)重新分配相關的架構感到滿意。
It would benefit us. We have not or we're not sizing that publicly at this point.
這會對我們有利。我們目前尚未、或說我們目前不會對外公開量化其影響。
And as we think about kind of our early look statements, just keep in mind the idea of being generally consistent is where we are standing here at third quarter. We'll give you much more detailed information as we get on our fourth quarter call. But I would say, I mean, we view the OPPS rule as proposed and we're hoping that it gets finalized here soon as a positive.
另外,談到我們對早期展望的說法,請記得我們目前在第三季所站的立場,是「大致維持一致」這個概念。等到第四季電話會議時,我們會提供更詳細的資訊。但我會說,我們把目前提出的 OPPS 規則視為正面因素,也希望它能很快定案。
Factor for ACA as we head into 2027.
作為我們邁向 2027 年時 ACA 的一項因素。
Operator
Operator
Ben Hendrix, RBC Capital Markets.
Ben Hendrix,RBC Capital Markets。
Ben Hendrix - Analyst
Ben Hendrix - Analyst
Great.
很好。
Thank you very much. And I appreciate the demand comments for next year and the expectation for 2% to 3% volume growth. I'm wondering how the surgical backdrop is fitting into your thoughts there. I know you had said that you didn't expect any recovery of the kind of weaker elective trend through the end of this year. But as we think about next year, is there pending demand getting pinned up there that could unwind and would that be upside to that 2% to 3% or would that. Considered in there. Any thoughts on how you're thinking about surgical progression for next year? Thanks.
非常感謝。我也很感謝你們對明年需求的評論,以及對 2% 到 3% 量(volume)成長的預期。我想了解外科手術的環境在你們的思考中是如何納入的。我知道你們先前說過,預期今年底前不會看到較疲弱的選擇性(elective)趨勢出現任何復甦。但當我們思考明年時,是否有被壓抑的需求正在累積、之後可能釋放,並成為 2% 到 3% 的上行空間,還是說。已經包含在該預期之中。你們對明年手術量的走勢有何看法?謝謝。
Samuel Hazen - Chief Executive Officer, Director
Samuel Hazen - Chief Executive Officer, Director
Ben, we haven't landed on components of that growth just yet. We have some viewpoints. I think again, we need to get through the fourth quarter, see how the seasonality on surgery plays out in the fourth quarter. I think our emergent business, as Mike spoke to. Continues to be strong. We see some macro forces impacting the elective business, coverage being the primary macro force, and then just sort of general affordability across the economy being a second one. So I think from that standpoint, we haven't landed on any surgical viewpoints. But I think it's important for everyone to understand that our composition of volume is fairly diverse.
Ben,我們目前還沒有把那個成長拆解到各個組成項目。我們有一些觀點。我想同樣地,我們需要先走完第四季,看看第四季手術量的季節性會如何表現。我認為我們的急症(emergent)業務,如 Mike 所提到的。仍然很強勁。我們看到一些宏觀因素正在影響選擇性業務,其中主要的宏觀因素是保險覆蓋(coverage),其次是整體經濟的可負擔性。所以從這個角度來看,我們還沒有就手術形成任何明確觀點。但我認為讓大家理解很重要的是,我們的量的組合相當多元。
We have women's. We have NICU. We have transplant programs. We have surgery, yes, medicine, critical care. All of these components are attributes of our company that we think give us an ability to navigate through a component not being as productive as we want. And that's what we're seeing. We're seeing more growth in other services that are compensating for some of the surgical growth or surgical declines that we're expecting. Experiencing. For example, our neonatal activity in the quarter was very strong. Our cardiac business continues to be strong. Our trauma business strong.
我們有婦女健康。我們有新生兒加護病房(NICU)。我們有移植計畫。我們有手術,沒錯,還有內科、重症照護。所有這些組成,都是我們公司的一些特質,我們認為這讓我們有能力在某個組成項目不如我們期望那麼有生產力時,仍能因應。而這正是我們目前看到的情況。我們看到其他服務的成長較多,正在彌補我們預期。所經歷的部分手術成長不足或手術下滑。例如,我們本季的新生兒活動非常強勁。我們的心臟業務持續強勁。我們的創傷業務也很強。
EMS traffic to our hospitals up significantly. So there's all of these elements that go into our volume assumption. We're not ready to sit there and call out surgery specifically for 2027 until we get a better viewpoint of it through the seasonality patterns that typically exist in the fourth.
救護車(EMS)送到我們醫院的量大幅增加。所以,所有這些要素都會納入我們對量的假設。在我們透過第四季通常存在的季節性型態,對其有更清楚的觀點之前,我們還不準備在 2027 年特別點名手術。
Operator
Operator
Brian Tanquilut, Jefferies.
Brian Tanquilut,Jefferies。
Brian Tanquilut - Equity Analyst
Brian Tanquilut - Equity Analyst
Hey, good morning, guys. Maybe, Mike, as I can look at the SWB and the operating expense lines, SWB up sequentially, other OpEx down, anything you can call out there, especially as we think through temp staffing, we're seeing indicators that it looks like temp versus staff orders are picking up, so just curious what you can share with us on those two line items, especially given resiliency efforts?
嗨,早安,各位。或許 Mike,當我看 SWB 與營運費用(operating expense)兩條線時,SWB 季比上升、其他 OpEx 下降,你能否說明一下其中原因,特別是當我們思考臨時人力配置時,我們看到一些指標顯示臨時人力相對於正式人力的需求似乎正在回升,所以想請教你能否分享這兩個科目的一些情況,尤其是在韌性(resiliency)措施的背景下?
Michael Marks - Chief Financial Officer, Executive Vice President
Michael Marks - Chief Financial Officer, Executive Vice President
Sure. And I mean, that's part of this answer is consistent with our sequential notes we had in my prepared comments, Brian.
當然。我的意思是,這個回答的一部分其實與我在事先準備的發言中、對季比變化的說明一致,Brian。
Typically when we go from second quarter to third quarter, that is the timing of when we do a lot of our merit adjustments in labor. And so we typically see, even 100 basis point increase in our expense for salaries and benefits overall.
通常我們從第二季進入第三季時,正好是我們進行許多勞動力績效調薪(merit adjustments)的時間點。因此我們通常會看到薪資與福利(salaries and benefits)整體費用上升,甚至可能增加 100 個基點。
And that's one of the factors. And so we were actually really pleased when we looked at our expenses per equivalent admissions, obviously excluding state supplemental payments.
這是其中一個因素。因此,當我們看每等值入院(equivalent admissions)的費用時,我們其實非常滿意,當然要排除州補充款(state supplemental payments)。
One, they were essentially flat to the prior year, but two, they were 40 basis points sequentially down, from second quarter to third quarter, which, we think really reflects the strength of not only our resiliency plan, but also the operating leverage we're getting from same-facility volumes. I mean, if you look at SWB on a margin basis to prior year, even with, the softer overall revenue, we had a 40 basis point margin, so we were.
第一,它們基本上與去年持平;第二,它們季比下降了 40 個基點,從第二季到第三季,這我們認為確實反映了不僅是我們韌性計畫的力道,也反映了我們從同院區(same-facility)量成長所取得的營運槓桿。我的意思是,如果你看 SWB 相對去年在毛利率(margin)上的表現,即使整體營收較疲弱,我們仍有 40 個基點的毛利率,所以我們。
With that and the same thing, we had good performance in supplies as well.
在這方面,以及同樣地,我們在耗材(supplies)上也有不錯的表現。
On other operating expenses, if you just look at third quarter to prior year, you do have a bit of cost related to the state supplemental payments, keep that in mind. Professional fees continue to be a pressure point for the company. We were up. About 12% versus prior year quarter, and professional fees now represent about 24% of other operating expenses.
至於其他營運費用(other operating expenses),如果你只看第三季相對去年,你確實會看到一些與州補充款相關的成本,請記得這點。專業費用(professional fees)仍然是公司的一個壓力點。我們較去年同期上升。約 12%,而專業費用目前約占其他營運費用的 24%。
And I would note that those continue to be driven by radiology and anesthesiology. So that's Brian, that's a bit of a rundown on the cost side.
我也要指出,這些仍主要由放射科(radiology)與麻醉科(anesthesiology)所驅動。所以 Brian,以上是成本端的大致說明。
Operator
Operator
Pito Chickering, Deutsche Bank.
Pito Chickering,Deutsche Bank。
Pito Chickering - Research Analyst
Pito Chickering - Research Analyst
Hey, good morning, guys, to take my question. I'm going to ask AJ's question a little differently. You quantify the $600 million or $550, $650 million of less Medicaid supplemental payments. You talked qualitatively about the HIX impact next year and the core mission growth of 2% to 3%. Can you just confirm that 2027 adjusted core EBITDA growth is still in the 4% to 6% range? The other piece is impacting that, or is core running hotter or lower? How much is resiliency driving that core growth?
嗨,早安,各位,謝謝讓我提問。我會用稍微不同的方式問 AJ 的問題。你們量化了 Medicaid 補充款(supplemental payments)減少 6 億美元,或 5.5 億到 6.5 億美元。你們也定性談到明年 HIX 的影響,以及核心使命(core mission)量成長 2% 到 3%。你們能否確認 2027 年調整後核心 EBITDA 成長仍在 4% 到 6% 的區間?還有其他因素在影響嗎,或是核心表現更熱或更冷?韌性措施對這個核心成長貢獻多少?
Michael Marks - Chief Financial Officer, Executive Vice President
Michael Marks - Chief Financial Officer, Executive Vice President
Well, resiliency is just part of our core operations. And so that's the way we think about resiliency is part of the work we do every day in management company.
嗯,韌性只是我們核心營運的一部分。因此,我們看待韌性的方式,就是把它視為我們在管理公司每天所做工作的其中一部分。
When I think about core growth in third quarter, we were pleased with core growth in third quarter and call it a 10% core growth increase.
當我想到第三季的核心成長時,我們對第三季的核心成長感到滿意,並稱其為核心成長增加10%。
I think that reflect good volume growth, it reflected a good net revenue per unit improvement in the quarter and really good cost management as well.
我認為這反映了良好的量的成長,也反映了本季每單位淨營收的良好改善,以及同樣非常好的成本管理。
And I think as you see how we kind of set the guidance range in the upper half of the range, that gives you an implication of how we're thinking about fourth quarter.
而且我認為,當你看到我們如何把指引區間設定在區間的上半部時,這也讓你對我們如何看待第四季有所意涵。
And then we'll give you kind of our thinking in more detail about 2027 when we get on our fourth quarter calls. So that would be the way to think about core growth.
接著,等到我們第四季電話會議時,我們會更詳細地向各位說明我們對2027年的想法。所以,這就是看待核心成長的方式。
We'll need to validate it for fourth quarter, but we were really pleased with third quarter. And you get a sense from the upper half of the range comment that we have.
我們仍需要在第四季加以驗證,但我們對第三季的表現非常滿意。而你也可以從我們提到「區間上半部」的評論中感受到這一點。
Operator
Operator
Matthew Gillmor, KeyBanc.
Matthew Gillmor,KeyBanc。
Matthew Gillmor - Equity Analyst
Matthew Gillmor - Equity Analyst
Hey, thanks for the question. On the pricing topic, you called out an acceleration in insured revenue per equivalent admissions. It sounded like that was better than expected. Can you talk about some of the drivers of that acceleration?
嗨,謝謝讓我提問。關於定價這個主題,你提到每等值入院的投保(insured)營收加速成長。聽起來這比預期更好。你能談談這個加速的幾個驅動因素嗎?
Michael Marks - Chief Financial Officer, Executive Vice President
Michael Marks - Chief Financial Officer, Executive Vice President
Sure. So, Matthew, if I look at kind of net revenue per unit and I think about the insured book, obviously, excluding the exchanges, because the payer mix is still the big negative that we're dealing with in terms of net revenue per unit to prior year. Number one is really the strength of our commercial volume. Our commercial excluding exchanges volume was up 2.7% over prior year quarter, and that's strong. And so that component of our payer mix.
當然。所以,Matthew,如果我看每單位淨營收,並聚焦在投保這一塊,顯然要排除交易所(exchanges),因為在與前一年相比的每單位淨營收方面,付款方組合(payer mix)仍是我們面臨的主要負面因素。第一個因素其實是我們商業保險量的強勁。我們的商業保險(不含交易所)量較去年同期成長2.7%,這很強。因此,這一塊在我們的付款方組合中……
Is definitely a part of why our net revenue per unit was a bit stronger in third quarter than the first half of the year.
確實是我們第三季每單位淨營收比上半年略強的原因之一。
The second, we continue to see solid rate growth across our payer categories.
第二,我們持續看到各付款方類別都有穩健的費率成長。
And then really third, Parallon, we see continued strengthening.
第三,Parallon 方面,我們看到持續的強化。
And their abilities to collect our net revenues and yield our contracts, their work to continue to strengthen our abilities to deal with denials and underpayments continues to improve. And so I think overall, we had a good net revenue per unit performance in the third quarter, especially kind of given the headwinds from our payer mix.
他們在收取我們淨營收、並提升合約實現率(yield)方面的能力持續增強;他們持續強化我們處理拒付(denials)與少付(underpayments)的能力,且持續改善。因此我認為整體而言,第三季我們的每單位淨營收表現不錯,尤其是在付款方組合帶來逆風的情況下。
Operator
Operator
Sean Dodge, BMO Capital Markets.
Sean Dodge,BMO Capital Markets。
Sean Dodge - Analyst
Sean Dodge - Analyst
Maybe just on the 2026 guidance, Mike, you said you're now pointing to the upper half of the range. I think that still implies core growth in Q4 will accelerate some from Q3. Maybe if you could just walk us through the visibility you have and what's going to drive that. Is that just incremental gains from. You're expecting to come through?
也許就2026年指引來問一下,Mike,你說你們現在指向區間的上半部。我認為這仍意味著第四季的核心成長會比第三季再加速一些。也許你可以帶我們走一遍你們目前的能見度,以及將由什麼來驅動?這是否只是來自……的增量改善?你們預期會實現的部分?
And Sam, you also mentioned volume growth in Q3 broadly improved from the first half of the year. Is that part of the assumption too that volumes also continue to improve in the Q4?
另外,Sam,你也提到第三季的量成長整體上比上半年有所改善。這是否也是假設的一部分,也就是第四季量也會持續改善?
Michael Marks - Chief Financial Officer, Executive Vice President
Michael Marks - Chief Financial Officer, Executive Vice President
Well, first, I would say, I mean, I think if you look at the upper half of our guidance ranges, that largely implies our core growth fairly consistent in the fourth quarter and third quarter would be the first thing out of context.
嗯,首先我會說,我的意思是,我認為如果你看我們指引區間的上半部,那在很大程度上意味著我們第四季的核心成長與第三季大致一致,這是第一點、先把脈絡說清楚。
And then I think the drivers are similar, number one is we did see strength in volume in third quarter and so that's encouraging for sure, we've already mentioned a little bit on the net revenue per unit side, there tends to be a step up from third quarter to fourth quarter.
接著我認為驅動因素也類似:第一,我們確實在第三季看到量的強勁,因此這當然令人鼓舞;我們也已經稍微提到每單位淨營收這一端,通常從第三季到第四季會有一個台階式上升。
In normal course. And so we expect that normal seasonal trend to apply broadly. And then we do believe, as even Sam mentioned, not only in his opening, but as we were talking about in the first question, that our performance around our resiliency plan, our ability to manage costs, we continue to see strength across our resiliency plan in third quarter, in fourth quarter and into 2027, 2028 and beyond. So I think those are the key components.
在正常情況下。因此我們預期這種正常的季節性趨勢會大致適用。另外,我們也相信——正如Sam提到的,不僅在他的開場,也如同我們在第一個問題中談到的——我們在韌性計畫上的表現、我們管理成本的能力,我們持續看到韌性計畫在第三季、第四季以及進入2027、2028乃至更長期都保持強勁。所以我認為這些是關鍵組成。
Sean, that are kind of making up our guidance comment for fourth quarter of 2026?
Sean,這些大致構成了我們對2026年第四季指引評論的內容?
Operator
Operator
Whit Mayo, Leerink.
Whit Mayo,Leerink。
Whit Mayo - Analyst
Whit Mayo - Analyst
Did the HIX headwind get larger in any particular market and any comments around AR collectability, balance after collectability would be helpful? And any of the $400 million, is that related to prior quarters?
HIX 的逆風是否在某些特定市場變得更大?另外,關於應收帳款(AR)可收回性、以及可收回性之後的餘額(balance after collectability)有任何評論都會很有幫助。還有,那4億美元之中,有任何部分是與前幾季相關嗎?
Michael Marks - Chief Financial Officer, Executive Vice President
Michael Marks - Chief Financial Officer, Executive Vice President
Well, I would say with that our HIX results in third quarter were a little bit higher than we estimated.
嗯,我會說,我們第三季的 HIX 結果比我們估計的略高一些。
We would have estimated based on our guidance that we gave at the second quarter, the third quarter would be 15%, 16% decline, we ended up at about 19% decline, which just reflects the sustained decline in our exchange volumes.
根據我們在第二季給出的指引,我們原本估計第三季會下滑15%到16%,但最後約下滑19%,這反映了我們交易所量的持續下滑。
I like to put that in context, though. I mean, that two or three points is about 2000 adjusted admissions.
不過我想把這放在脈絡中看。我的意思是,那2到3個百分點大約是2,000個調整後入院(adjusted admissions)。
We have about a million adjusted admissions in the quarter. So these aren't perfect estimates, but it gives you a sense of the numbers we're looking at here.
我們單季大約有100萬個調整後入院。所以這些估計不會是完美的,但能讓你感受到我們在看哪些數字。
Our experience in third quarter, and I mentioned this in my prepared comments, number one, third quarter of last year was our high watermark, so there was a bit of a prior year comparison difficulty.
我們第三季的經驗——我在事先準備的發言中也提到——第一,去年第三季是我們的高水位(high watermark),因此在與前一年比較時確實有些難度。
We did see, however, a sequential improvement in exchange volume from second quarter to third quarter '26 of about 8%. And so all of that when we brought it together, it's kind of what guided us. To say that we think for full year '26 now, we'll be at to maybe slightly above the top end of our previously updated ranges for the exchanges.
不過我們確實看到,從第二季到2026年第三季,交易所量按季改善約8%。因此把這些因素綜合起來後,這大致就是引導我們……去表示我們認為2026年全年現在會落在、或可能略高於我們先前更新後區間的上緣(針對交易所)。
That's kind of how the numbers pulled through here in third quarter.
這就是第三季這些數字在這裡反映出來的方式。
Operator
Operator
Ryan Langston, TD Cowen.
Ryan Langston,TD Cowen。
Ryan Langston - Analyst
Ryan Langston - Analyst
Great. Thanks. Appreciate the commentary on elective versus emergency surgical future trend growth. Can you maybe update us on what ASC versus HOPD surgical volume look like in the third quarter? Thanks.
很好。謝謝。感謝你們對選擇性(elective)與急診(emergency)手術未來趨勢成長的評論。你能否更新一下第三季 ASC 相對於 HOPD 的手術量看起來如何?謝謝。
Michael Marks - Chief Financial Officer, Executive Vice President
Michael Marks - Chief Financial Officer, Executive Vice President
So the ASC surgery volumes were down 5.4% on surgery. Overall, case volumes were down about 3.7%.
所以 ASC 的手術量在手術方面下滑5.4%。整體而言,病例量(case volumes)下滑約3.7%。
The primary pressure is related to the exchanges in our ASC book, very similar to the hospital side. I wouldn't know, however, that even in light of the volume softness there, that our overall net revenue and earnings did show some growth to prior year.
主要壓力與我們 ASC 組合中的交易所有關,與醫院端非常類似。不過我也要指出,即便那裡的量偏弱,我們整體的淨營收與獲利相較去年仍呈現一些成長。
The hospital-based outpatient surgeries were down 2.9%.
以醫院為基礎的門診手術量下滑了2.9%。
Samuel Hazen - Chief Executive Officer, Director
Samuel Hazen - Chief Executive Officer, Director
I think it's important to understand the construct of our ASC platform, and that informs at some level for us the macro forces that are out there with elective care at this particular juncture.
我認為理解我們ASC平台的架構很重要,而這在某種程度上也讓我們能掌握在此時點、與選擇性醫療相關的外部總體力量。
And so when you sort through what's going on, there are certain issues in some centers that we have, but at sort of an aggregated level, it informs. A little bit of our macro thinking around some of those forces that are influencing overall demand.
因此,當你梳理目前發生的情況時,我們在部分中心確實有一些特定問題,但從彙總層面來看,這些情況也提供了參考。讓我們在總體層面思考那些正在影響整體需求的力量。
Operator
Operator
Sarah James, Cantor Fitzgerald.
Sarah James,Cantor Fitzgerald。
Sarah James - Analyst
Sarah James - Analyst
I'd like to keep going on that topic. So is there a way to unpack.
我想延續這個主題。所以,有沒有辦法拆解一下。
Unpack how much of the inpatient and outpatient surgical trend pressure so far this year is exchange-related versus how much is affordability and things that may be continuing?
拆解一下今年迄今住院與門診手術趨勢所承受的壓力,有多少是與交易所(exchange)相關,另有多少是可負擔性以及可能會持續的其他因素?
And then given your comment on affordability pressure, are you assuming any stronger than normal tailwind in 4Q ahead of the deductible reset?
另外,基於你對可負擔性壓力的評論,你們是否假設在免賠額重置前的第四季會有任何強於正常的順風?
Samuel Hazen - Chief Executive Officer, Director
Samuel Hazen - Chief Executive Officer, Director
We are not at this particular juncture assuming anything outside of normal seasonality, but your point is relevant. It could be that some folks are.
在目前這個時間點,我們不假設任何超出正常季節性的因素,但你的觀點是有關聯的。有可能有些人正在。
Making decisions. We've seen that on the margins in other years, but at this particular point in time, we are not. When I look at our elective care, surgical care, I mean, the HIX is a very large percentage of the explanation. It goes back to what we've been saying all of last year and all of this year. Coverage for people matters, and it creates access, affordability, and elective care. It's a very fundamental element to individuals' abilities to get the healthcare they need. And so it's a large piece of the elective equation is the coverage dynamic that's occurred in the HIX environment. And I don't have an exact percentage here in front of you, but it's a very significant piece of the variance. And we called that out and we think that has some incremental effects in other. Payer classifications as well as we talk about the affordability more broadly.
做出決策。我們在其他年度的邊際上確實看過這種情況,但就目前而言,我們沒有。當我看我們的選擇性醫療、外科醫療時,我的意思是,HIX在解釋上占了非常大的比重。這回到我們去年一整年以及今年一直在說的:人們是否有保險覆蓋很重要,因為它會帶來可近性、可負擔性,以及選擇性醫療。這是影響個人取得所需醫療照護能力的一個非常根本的要素。因此,在選擇性醫療的方程式中,很大一部分來自於HIX環境中所發生的保險覆蓋動態。我手邊沒有精確百分比,但它是造成差異的一個非常顯著的部分。我們也點出這一點,並且我們認為它也會在其他。付款方分類上帶來一些增量影響,正如我們更廣泛地談到可負擔性一樣。
Operator
Operator
Justin Lake, Wolfe Research.
Justin Lake,Wolfe Research。
Justin Lake - Analyst
Justin Lake - Analyst
Thanks. Good morning. A couple of quick number follow-ups. First on 2027 DPP, appreciate the 550 to 650 number. I was hoping you can isolate your estimate here of how much of that number comes from the Q4 DPP cut as HR1 gets implemented versus the 2026 at a period that doesn't reoccur. And then on the exchange impact for Q4, can you tell us how much your guidance assumes that that sequential exchange. Volume growth occurs from Q3 to Q4 this year? I know you just gave us the Q2 to Q3 numbers on Q3 to Q4.
謝謝。早安。有幾個快速的數字追問。首先關於2027年DPP,感謝提供5.5億到6.5億美元的數字。我想請你們把你們的估計拆開:其中有多少是因HR1開始實施而導致第四季DPP削減所造成,另有多少是2026年一次性的、跨期(不會重複發生)的因素。另外,關於第四季交易所的影響,你們能否告訴我們,你們的指引假設今年從第三季到第四季交易所。量會有多少的季增?我知道你們剛剛給了我們第二季到第三季的數字,但我問的是第三季到第四季。
Michael Marks - Chief Financial Officer, Executive Vice President
Michael Marks - Chief Financial Officer, Executive Vice President
Well, let me start the first part of your question. So as Sam noted in his comment, we expect to receive approximately $550 million to $650 million less. In Medicaid state supplemental payment net benefit in 2027 versus 26, and that's because of the grandfather approvals that happened in 26 that were really related to prior years.
好,我先回答你問題的第一部分。如Sam在他的評論中提到的,我們預期在2027年相較於2026年,將少收到約5.5億到6.5億美元。的Medicaid州補充支付(state supplemental payment)淨收益,原因是2026年發生的既有條款(grandfather)核准,實際上是與前幾年相關。
The predominance of that, Justin, was related to Florida, which we previously disclosed.
其中占比最大的部分,Justin,是與佛羅里達州相關,我們先前已揭露過。
The rest is really related to the other grandfathered states, like Virginia, Georgia, et cetera. So that's really the makeup of those kind of the out of period state supplemental payment programs. If I think about what the guidance implies of fourth quarter, we are finishing September 26th. Six year-to-date with $650 million of incremental net benefit from state supplemental payments.
其餘部分主要與其他既有條款州相關,例如維吉尼亞州、喬治亞州等等。所以,這就是那些跨期的州補充支付計畫的構成。如果我看指引對第四季的含意,我們在9月26日結束。年初至今已取得6.5億美元的州補充支付帶來的增量淨收益。
So if you think about the full year guidance range that we just updated to $600 to $800 million, that would give you a sense for what we're thinking about fourth quarter. At midpoint, it would be another $50 million net incremental benefit, and then you can see the range. And so that's kind of how we're thinking about that for fourth quarter.
因此,如果你看我們剛更新的全年指引區間為6億到8億美元,你就能大致了解我們對第四季的看法。以中位數來看,將再增加5,000萬美元的淨增量收益,你也可以看到其區間。這就是我們對第四季的思考方式。
And then on exchanges.
接著談交易所。
Not ready to quote a sequential move from Q3 to Q4 at this point. I would note, and we noted this on our second quarter call, I would point you back to fourth quarter of '25, where we did see a slowdown occur in our exchange volumes from Q3 to Q4 last year. And so we do think there is a bit of a benefit comparison benefit in fourth quarter of '26 given that factor.
目前還不準備給出從第三季到第四季的季比變動幅度。我想指出,而且我們在第二季電話會議也提到過,我會請你回顧2025年的第四季,當時我們確實看到去年交易所量從第三季到第四季出現放緩。因此,考量到這個因素,我們確實認為2026年第四季在比較基期上會有一些有利因素(comparison benefit)。
Operator
Operator
Kevin Fischbeck, Bank of America.
Kevin Fischbeck,美國銀行。
Kevin Fischbeck - Analyst
Kevin Fischbeck - Analyst
Great, thanks. A lot of moving pieces here. So I just want to make sure I understand the new guidance versus the old guidance. Is the right way to think about it that.
很好,謝謝。這裡有很多變動因素。所以我只是想確認我理解新的指引相對於舊的指引。正確的理解方式是否是。
The new guidance includes about $300 million more of SDPs and $100-plus million more of headwinds from payer mix and then that combination is largely the increase in guidance from.
新的指引包含約3億美元更多的SDP,以及因付款方組合(payer mix)帶來的1億多美元額外逆風,而這兩者的組合大致就是指引上調的主要原因。
The prior? Is that the right way to think about it? And then just a clarification on the HIX headwind that you guys are talking about. Is it purely just an uninsured number, people coming in and not paying? Or are you also kind of thinking about the implication of lost surgery for the people losing coverage in that number?
相較於先前?這樣理解對嗎?另外想釐清一下你們提到的HIX逆風。它純粹只是無保險人數的問題,也就是人進來但不付錢?還是你們也把失去保險覆蓋的人因此少做手術的影響納入這個數字?
Michael Marks - Chief Financial Officer, Executive Vice President
Michael Marks - Chief Financial Officer, Executive Vice President
Well, let's walk to guidance first, Kevin. So yes, I mean, from supplemental payments, we've raised our net benefit guidance by about $300 million. So that's certainly a piece of it. If you think about the exchanges with this idea of kind of at or slightly above the top end in our previously released estimates.
Kevin,我們先從指引的拆解開始。是的,就補充支付而言,我們把淨收益指引上調了大約3億美元。所以這當然是其中一部分。如果你看交易所,基於我們先前發布的估計,現在的假設是落在區間上緣或略高於上緣。
You're in the $100 million to $200 million increase in headwinds related to that. And then the third thing I would call out is just core growth. I mean, I think as we noted on today's call, we believe our fourth quarter core growth should be good. The net of those three factors really led us to making the comment that we believe will be in the upper end of our guidance ranges for the full year, which will give you a sense of how all that comes together.
因此,與此相關的逆風增加約1億到2億美元。第三點我想強調的是核心成長。我的意思是,正如我們在今天的電話會議中提到的,我們認為第四季的核心成長應該不錯。這三個因素加總後,讓我們做出評論:我們認為全年結果將落在指引區間的上緣,這也能讓你理解這些因素如何匯總在一起。
So that would be the walk down guidance.
以上就是指引的拆解。
Operator
Operator
Scott Fidel, Goldman Sachs.
Scott Fidel,高盛。
Scott Fidel - Analyst
Scott Fidel - Analyst
Hi, thanks, good morning.
嗨,謝謝,早安。
My question is just first on the i know there's been some questions around it on the third quarter and next year, but on the fourth quarter, just maybe the visibility and expectations that you have around elective procedures and sort of how scheduling seems to be playing out in terms of just normal seasonality.
我的問題首先是關於——我知道大家對第三季和明年有一些提問——但就第四季而言,想請你談談你們對選擇性手術的能見度與預期,以及在排程方面看起來是否只是正常的季節性表現。
And then I just wanted to also ask in terms of the headwinds that you've laid out for next year relating to DPP, whether there's anything specifically relating just to the CMS policy that now is requiring all the 1115 waivers to be budget neutral from a federal perspective and just whether your intel from the states, are you seeing any change in sort of approach or in terms of applications or.
接著我也想問一下,關於你們所提到明年與 DPP 相關的逆風,是否有任何因素是特別與 CMS 的政策有關,也就是現在要求所有 1115 豁免(waivers)從聯邦角度必須達到預算中立(budget neutral);以及根據你們從各州取得的資訊,你們是否看到在做法上、申請內容或申請趨勢方面有任何變化,或是……
Sort of anything that you think could be sort of play out, relating to that policy that could impact fundamentals in 2027. Thanks.
任何你認為可能會因該政策而出現、並可能影響 2027 年基本面(fundamentals)的情況。謝謝。
Michael Marks - Chief Financial Officer, Executive Vice President
Michael Marks - Chief Financial Officer, Executive Vice President
On elective, Scott, and I think Sam mentioned this when he was answering the previous question of surgery. At this point, we did not assume, any pickup on elective demand related to.
關於選擇性(elective)需求,Scott,我想 Sam 在回答前一個關於手術的問題時也提到過。就目前而言,我們並沒有假設會有任何與……相關的選擇性需求回升。
Co-pays and deductibles in the fourth quarter. I think we expect a normal seasonal move from Q3 to Q4, but we did not build into our guidance thinking some kind of improvement or pull forward of demand from an elective standpoint in the fourth quarter.
第四季的自付額(co-pays)與免賠額(deductibles)。我想我們預期從第三季到第四季會有正常的季節性變動,但我們沒有在指引中納入任何假設,認為第四季在選擇性需求方面會有某種改善或需求提前(pull forward)。
When I think about HR1 for 2027, and we continue to monitor all the rulemaking, we know that our states continue to file their applications and feel good about the processes that we see. in flight.
至於 2027 年的 HR1,我們會持續監控所有的規則制定(rulemaking)。我們知道各州仍在提交其申請,且對我們看到的流程感到樂觀。目前都在進行中(in flight)。
I would mention on HR1 that, the big change is really work requirements for able-bodied adults in our expansion states.
我想就 HR1 補充一下,最大的變化其實是對我們擴張州(expansion states)中具工作能力的成年人(able-bodied adults)施加工作要求(work requirements)。
I might mention just for context that expansion states are 40% of our Medicaid volumes and revenues. And when you think about work requirements targeting able-bodied adults in those expansion states.
我也補充一些背景:擴張州約占我們 Medicaid 量與收入的 40%。而當你想到在這些擴張州針對具工作能力成年人設定工作要求時……
When you take out the seniors and the disabled and the kids and those that are medically frail, we think that work requirements would be kind of applicable to about 15% to 20% of our Medicaid volume.
扣除高齡者、身心障礙者、兒童以及醫療上屬於脆弱(medically frail)的人群後,我們認為工作要求大概會適用於我們 Medicaid 量的約 15% 到 20%。
And so the net of all of that, while we're not quite ready to size it in terms of earnings impact, we do think that work requirements specifically would have a bit of a modest impact in full year '27. So that's some main things we're watching for HR1 next year, and I think that wraps both of your questions.
因此綜合來看,雖然我們還沒準備好以獲利影響來量化,但我們確實認為,工作要求本身在 2027 全年會帶來一些溫和的影響。以上是我們明年針對 HR1 主要在關注的事項,我想也回答了你們兩個問題。
Operator
Operator
Stephen Baxter, Wells Fargo.
Wells Fargo 的 Stephen Baxter。
Stephen Baxter - Analyst
Stephen Baxter - Analyst
Just a couple of follow-ups on the breakout of adjusted admissions. I think you gave us the commercial exchange number already, but could we get the Medicare, your AA growth, Medicaid, and then I guess you gave us the exchanges on a quarter-over-quarter basis. If you also had the year-over-year basis, that would be helpful too.
我有幾個關於調整後入院(adjusted admissions)拆分的追問。我想你們已經給了商業交換市場(commercial exchange)的數字,但是否可以提供 Medicare 的 AA 成長、Medicaid 的,以及(我想你們已經給了)交換市場的季對季數字。如果也能提供年對年數字,會很有幫助。
Michael Marks - Chief Financial Officer, Executive Vice President
Michael Marks - Chief Financial Officer, Executive Vice President
Sure.
當然。
So the same-facility adjusted admissions compared to prior year for third quarter, Medicare is up 3.2%, Medicaid is up 2.7%, commercial excluding the exchanges are up 2.7%, and then the exchanges are down 19% in the prior year quarter.
第三季同院(same-facility)調整後入院相較去年同期:Medicare 上升 3.2%,Medicaid 上升 2.7%,不含交換市場的商業保險上升 2.7%,而交換市場相較去年同期下降 19%。
As I noted in my comments ago, that is an 8% sequential improvement from Q2 to Q3.
如我先前提到,這代表從第二季到第三季有 8% 的連續改善(sequential improvement)。
Operator
Operator
Jason Cassorla, Guggenheim Securities.
Guggenheim Securities 的 Jason Cassorla。
Jason Cassorla - Equity Analyst
Jason Cassorla - Equity Analyst
Great, thanks. Good morning. I wanted to turn back to the volume discussion.
很好,謝謝。早安。我想回到量(volume)的討論。
You guys have seen pretty solid volume acceleration over the past couple of quarters that clearly stands out. You're talking about 2% to 3% volume growth next year. I was just hoping if you can give us a little more in terms of what you're attributing the volume strength to. I mean, you've talked to the solid demand environment, but can you help quantify maybe like how much you're thinking is coming from the benefits of in-market initiatives, all the work you've done to expand capacity and the like, and how that kind of fits into that 2% to 3% mold that you're looking forward for next year would be helpful.
你們在過去幾個季度看到相當穩健的量加速,這點非常突出。你們談到明年量成長 2% 到 3%。我想請你們多談一些,你們把量的強勁歸因於哪些因素。我的意思是,你們提到需求環境穩健,但能否協助量化一下,例如你們認為有多少來自於在地市場(in-market)策略的效益、你們為擴充產能所做的各項工作等等;以及這些如何對應到你們對明年 2% 到 3% 的展望,會很有幫助。
Samuel Hazen - Chief Executive Officer, Director
Samuel Hazen - Chief Executive Officer, Director
So if you start at the top here, I mean, it's our belief that there's sort of inherent demand growth in the markets that we serve coming from population growth.
如果從最上層來看,我們的看法是,我們所服務市場存在某種內生的需求成長,來自人口成長。
Aging baby boomers, chronic conditions, new technology even, all of this sort of converges to create an upward movement in demand in the markets that we serve.
嬰兒潮世代老化、慢性病、新技術等,這些因素匯聚在一起,推動我們所服務市場的需求上升。
And so that's just the starting point. We do think across a lot of our markets, we're gaining market share incrementally. We do have some markets that we have to adjust to different dynamics and respond at that level. But when you look at it in the main, over time, we picked up market share. Our approach to our networks is continuing to advance.
所以那只是起點。我們確實認為,在許多市場我們正逐步提升市占率。也有一些市場我們必須因應不同的動態並在該層級做出調整。但整體而言,隨著時間推移,我們確實取得了市占。我們對於網絡(networks)的做法也在持續推進。
With respect to our ambulatory platform, we're up to almost 3,000 units.
就我們的門診平台(ambulatory platform)而言,我們已接近 3,000 個據點(units)。
Through acquisition of urgent care, ambulatory surgery centers and other outpatient facilities that complement our hospital's ecosystem and create for our patients a more convenient and accessible location and efficient service.
透過收購急診照護(urgent care)、門診手術中心(ambulatory surgery centers)以及其他可補強我們醫院生態系的門診設施,為病患提供更便利、更可及的地點與更有效率的服務。
That continues to evolve in our networks and as we.
這在我們的網絡中持續演進,而當我們……
Mature on that platform and leverage the restructuring that we did with one of our group Presidents, Charles Gresley. I anticipate that we're going to be able to move our ambulatory platform forward and create even more growth out of it. Again, meeting our customers, our patients, wherever they live so that we can create convenience and so forth for them. A second important initiative for us is creating patient. Coordination once they do hit one of our ambulatory facilities. And through patient coordination, we think we can create a better experience for the patient and ultimately integrate them into our system. And if in fact they need acute care services, we're helping them achieve that in an efficient and transparent way. So that's evolving also.
在該平台上更趨成熟,並運用我們與其中一位集團總裁 Charles Gresley 所做的重整(restructuring),我預期我們能進一步推動門診平台,並從中創造更多成長。
Clearly, we're investing in our hospitals. With capital, we are adding beds. We're adding other capacity within our facilities to manage the demand. We're running the company at an all-time high when it comes to occupancy levels, pushing 75% on our inpatient platform.
很明顯地,我們正在投資我們的醫院。在資本支出方面,我們正在增加病床。我們也在院內增加其他產能以管理需求。就住院平台而言,我們的住院率(occupancy)正處於歷史高點,接近 75%。
We're benefiting, however, through patient flow initiatives where we're able to improve the flow for our patients and get them to the care sites they need. That's creating capacity for. Us as we evolve also. So all of these things combined are yielding growth for our company. And then lastly, it's how we engage with our physicians and support our physicians with their practices, meet them where they are, and find ways to invest in clinical capabilities, be very effective and efficient in how we process their patients, and then ultimately give them a voice in what's going on that's allowing us. To respond largely to our physician requirements as well. So all of those things, it's impossible to point to one thing. And each market's slightly different. We have to nuance our approach in each market to address those differences. That's why we're organized as we are with our divisions. But I think with 22 consecutive quarters of growth in volume.
不過,我們也受益於病患流動(patient flow)相關的倡議,讓我們能改善病患動線,將他們送到所需的照護據點。這也在為……我們創造產能,並隨著我們持續演進。因此,所有這些因素結合起來,正在為公司帶來成長。最後,是我們如何與醫師互動、如何支持醫師的診所營運,在他們所在之處與他們合作,並尋找投資臨床能力的方法;在處理其病患時做到非常有效率且具效能,並最終讓他們對正在發生的事情有發聲管道,這也讓我們得以……在很大程度上回應醫師的需求。所以這些因素,很難只指向單一原因。而且每個市場都略有不同。我們必須在每個市場以更細緻(nuance)的方式調整做法,以因應差異。這也是我們以事業部(divisions)方式組織的原因。但我想,若以連續 22 個季度的量成長來看。
Which is quite impressive from my standpoint. And then with the return on capital and then with the improvements in quality and service for our patients, we feel like our model works and gives us, again, the staying power that I mentioned in my comments and allows us to push into the future with confidence and a belief that we can achieve our objectives.
從我的角度來看,這相當令人印象深刻。接著,隨著資本報酬率的提升,以及我們在病患照護品質與服務上的改善,我們認為我們的模式行得通,並再次帶給我們我在評論中提到的持久力,讓我們能夠有信心地推進未來,並相信我們可以達成目標。
Operator
Operator
Raj Kumar, Stephens.
Raj Kumar,Stephens。
Raj Kumar - Equity Analyst
Raj Kumar - Equity Analyst
Maybe on the pricing conversation, just curious on.
也許就定價的討論,我只是好奇想問。
I know you're mostly contracting on the commercial side for 2027, but you have to think about 2028. Are payers starting to embed any explicit assumptions around coding and more accuracy on that front? And just curious across one of that node in terms of how diffused it is across the platform, or is it still in early stages around kind of the coding on that front?
我知道你們在商業保險端多數是在談 2027 年的合約,但你們也必須思考 2028 年。保險支付方是否開始在編碼(coding)以及在這方面更高的準確性上,納入任何明確的假設?另外也好奇,就其中一個節點來看,這在整個平台上的擴散程度如何,還是說在這方面的編碼仍處於早期階段?
Samuel Hazen - Chief Executive Officer, Director
Samuel Hazen - Chief Executive Officer, Director
This is Sam. Let me lift up a little bit on this point. It's important for us to have solid relationships with the major payers.
我是 Sam。我來稍微補充說明一下這點。對我們而言,與主要支付方維持穩固的關係很重要。
In our community, and we do that.
在我們的社區裡,我們確實也這麼做。
And we're able to meet their objectives and meet our objectives in most circumstances. And that's been, I think, part of our ability to execute our strategy and help them execute their strategy. Our contracting process is transparent with our major payers, and we are accomplishing.
而且在多數情況下,我們能同時滿足他們的目標,也滿足我們的目標。我認為這也是我們能夠執行自身策略、並協助他們執行其策略的一部分原因。我們與主要支付方的簽約流程是透明的,而我們也正在完成。
Contract cycling that naturally occurs over time. We're deep into 2027, and we're not as deep into 2028, but we are making progress on 2028 as contracts mature and move into the cycle that naturally occurs. We're able to achieve our objectives and then support the objectives of the major payers.
隨時間自然發生的合約輪替(contract cycling)。我們在 2027 年的進度已經很深入,對 2028 年則還沒那麼深入,但隨著合約成熟並進入自然發生的週期,我們也正在推進 2028 年的進度。我們能夠達成我們的目標,同時支持主要支付方的目標。
Our teams are working very.
我們的團隊正在非常。
Earnestly to come up with solutions for people. And what I mean by that is the patient, the providers, and the beneficiaries that are all connected to what we do administratively between the insurance companies and the hospitals, HCA and many of the major payers are working.
努力地為大家提出解決方案。我的意思是,病患、醫療提供者,以及所有與我們在保險公司與醫院之間(行政作業層面)所做的事情相關聯的受益人;HCA 與許多主要支付方都在合作。
Diligently to eliminate the friction, create a more cost-effective solution, and reduce the administrative complexity that exists within the system. And I'm encouraged by the progress that we're making. I'm encouraged by the attitudes of many of the payers. And I think we're going to progress.
勤勉地消除摩擦、創造更具成本效益的解決方案,並降低體系內既有的行政複雜度。我對我們正在取得的進展感到鼓舞。我也對許多支付方的態度感到鼓舞。我認為我們會持續推進。
Over the next year or so and really create value for our patients and for the beneficiaries in a manner that starts to change the paradigm a little bit between what's going on with payers and what's going on with HCA. So more to come on that, but we are, in fact, progressing on just about every front with respect to our major payers.
在接下來一年左右,真正以一種方式為我們的病患與受益人創造價值,並開始在支付方與 HCA 之間正在發生的事情上,稍微改變既有的典範。因此後續還會有更多內容,但事實上,就我們與主要支付方相關的幾乎每一個面向,我們都在取得進展。
Operator
Operator
Benjamin Rossi, JPMorgan.
Benjamin Rossi,JPMorgan。
Benjamin Rossi - Analyst
Benjamin Rossi - Analyst
Hi, good morning. Thanks for the question. Following up on your market-specific commentary, with some of the broader operational pressures you're facing, I appreciate that you're still adding inpatient capacity and outpatient density.
嗨,早安。謝謝讓我提問。延續你們對特定市場的評論,在你們面臨一些更廣泛的營運壓力之下,我理解你們仍在增加住院容量與提升門診密度。
But as you assess your questions, are you at all considering any market exits or potential changes to your footprint? Or with these pressures hitting everyone, do you consider yourself a potential buyer as competitors to always face these headwinds? I guess just curious where you stand on market positioning at this juncture?
但當你們評估這些問題時,你們是否有在考慮退出某些市場或對你們的版圖做出任何可能的調整?或者在這些壓力影響到所有人的情況下,你們是否把自己視為潛在買方,因為競爭對手也同樣面臨這些逆風?我想只是好奇,在這個時間點你們對市場定位的看法是什麼?
Samuel Hazen - Chief Executive Officer, Director
Samuel Hazen - Chief Executive Officer, Director
So we compete in.
所以我們競爭於。
43 markets roughly in the U.S. Some of them are smaller and they get counted in that. And then some are mega markets. And over the last seven, eight years, we have been fairly intentional about looking at our individual markets and determining whether or not we can execute our model and be successful and meet the needs of our constituents. And we've largely pruned the portfolio of ACA. Down to the markets that we think can go the distance. And today, the markets that we have are ones that we're investing in at different levels, as you would expect, because of the different circumstances from one market to the other, the different opportunities that exist. So I don't see any significant change to our market configuration at this particular point because we've been intentional over the past few years. To optimize the portfolio, if you will, and put ourselves in a position where we can succeed and build out the model that we think adds value to our patients and adds value to the organization as a whole.
美國大約 43 個市場。其中有些市場較小,也被計入其中。另外也有一些是超大型市場。在過去七、八年,我們相當有意識地檢視各個單一市場,並判斷我們是否能夠執行我們的模式、取得成功,並滿足我們利害關係人的需求。而我們在很大程度上已經修剪了 ACA 的投資組合,縮減到我們認為能夠走得長遠的市場。而今天,我們所擁有的市場,是我們以不同層級在投資的市場,這也符合你的預期,因為各市場之間的情況不同、存在的機會也不同。因此在目前這個時間點,我不認為我們的市場配置會有任何重大改變,因為過去幾年我們一直是有意識地。去優化投資組合(如果你願意這麼說),並讓自己處於能夠成功、並擴建我們認為能為病患帶來價值、也能為整體組織帶來價值的模式的位置。
That allows us to focus our capital spending, to focus our talent and our resources on a smaller footprint, but with a very significant growth.
這也讓我們能把資本支出、人才與資源聚焦在較小的版圖上,但我們相信公司仍有非常顯著的成長。
Prospect we believe for the company. So that's where we are. We always have one or two items here or there.
前景。所以我們目前就是這樣的狀態。我們總是會有一兩個零星的事項。
With regard to new markets, you're right, we're built to be bigger. We know that, but we just haven't seen a lot of opportunities yet. If opportunities do develop.
至於新市場,你說得對,我們的架構是為了做得更大。我們知道這點,但目前還沒有看到很多機會。如果機會真的出現。
As usual, we'll be opportunistic and take a look at whether or not it's affordable, whether or not we can execute our model and make the right decision at that particular juncture.
一如往常,我們會把握機會並評估是否負擔得起、是否能執行我們的模式,並在當下做出正確的決策。
We do have a lot of outpatient activity, as I mentioned earlier, that is important to building out.
如我先前提到,我們有很多門診端的活動,這對於擴建。
The network overall so that it is accessible for our patients and we continue to invest in those opportunities as they develop as well.
整體網絡、讓病患更容易取得服務非常重要;我們也會隨著這些機會的出現持續投資。
Operator
Operator
Andrew Mok, Barclays.
Andrew Mok,Barclays。
Andrew Mok - Analyst
Andrew Mok - Analyst
Hi, good morning. Can you talk about what you're seeing in the market as it relates to the removal of the inpatient only list, both in terms of procedure migration today and actions taken now in anticipation of future migration? And how should we think about the impact of the inpatient only list and potential outpatient capacity additions against the backdrop of fixed surgeons? Thanks.
嗨,早安。你能談談你們在市場上看到的情況嗎?這與取消「僅限住院(inpatient only)」清單有關,包含目前手術向門診移轉的情形,以及為了因應未來可能的移轉而現在採取的行動?另外,在外科醫師人力固定的背景下,我們應該如何看待「僅限住院」清單的影響,以及可能新增的門診容量?謝謝。
Michael Marks - Chief Financial Officer, Executive Vice President
Michael Marks - Chief Financial Officer, Executive Vice President
Andrew, if I think about the inpatient-only list, obviously, we're in year one of a period here phased out.
Andrew,如果我來看「僅限住院」清單,顯然我們正處於分階段取消的第一年。
This first year is focused a bit more on ortho and musculoskeletal type procedures, so that's what we're seeing.
第一年比較聚焦在骨科與肌肉骨骼類型的處置,因此我們看到的主要就是這些。
I think if I look at our elective book, I would say after these changes, which were the biggest driver of elective surgical volume weakness, the second driver would have been Medicare, especially on the inpatient side, so we are seeing some.
我想如果我看我們的選擇性手術量,我會說在這些變更之後——而這些變更是選擇性手術量疲弱的最大驅動因素——第二個驅動因素會是 Medicare,尤其是在住院端,因此我們確實看到一些。
Some impact of the inpatient only list.
「僅限住院」清單帶來的一些影響。
I think it's fair to say that the outpatient market for surgery is a bit larger than the inpatient market for surgery. There's more competitors, and so that's a factor.
我認為可以公平地說,手術的門診市場比住院市場稍微更大。競爭者也更多,因此這是一個因素。
When I think broadly though, we look at ambulatory surgery centers, as Sam just walked through, as part of our networks. And building out our ambulatory networks, they play an important role.
但從更宏觀的角度來看,我們把門診手術中心(ambulatory surgery centers),如同 Sam 剛才所說,視為我們網絡的一部分。而在建構我們的門診網絡時,它們扮演著重要角色。
We are continuing to invest in our operating rooms and our surgical platforms in the inpatient side and the hospital side for outpatient surgery and in our ASC platforms and believe that it's a long-term important component. I don't think that anything we're seeing would say that it would drive a material change in the way we're approaching building out our networks.
我們持續在住院端的手術室與外科手術平台、醫院端的門診手術,以及我們的 ASC 平台上進行投資,並相信這是長期而言非常重要的一個組成部分。我不認為我們目前看到的任何情況,會促使我們在建構網路的方式上做出重大的改變。
Samuel Hazen - Chief Executive Officer, Director
Samuel Hazen - Chief Executive Officer, Director
And again, Mike, I think.
再說一次,Mike,我認為。
The fact that we have 25 different service categories that we focus on across the company that are different gives us an ability at times to invest, just like I said, in different markets. We can invest in different services depending on demand forecasts, population trends, competitive dynamics, and so forth. And you see that in our volumes when it comes to some of the pressures we. Seen on elective care, we've all set that with other services that give the networks a level of resiliency, give the demand sort of equation inside of the market support. When it comes to our ability to provide patient care. And I'm not sure that is fully recognized in some of these isolated discussions about service A, service B. Clearly, there are always issues. We've had issues with stuff migrating from inpatient to outpatient.
我們在全公司聚焦的 25 個不同服務類別,彼此之間的差異,讓我們在某些時候能夠投資——就像我說的——在不同市場。我們可以依據需求預測、人口趨勢、競爭態勢等等,投資於不同的服務。而你也能從我們的量能中看到,當面對某些壓力時,我們在……在選擇性醫療(elective care)方面所看到的壓力,我們都用其他服務來加以平衡,讓網路具備一定程度的韌性,並在市場內部為需求方程式提供支撐。就我們提供病患照護的能力而言。我不確定在一些針對服務 A、服務 B 的零星討論中,這點是否被充分認知。當然,問題總是會有。我們也曾遇到一些服務從住院轉移到門診的情況。
Over the years, we've had new technologies evolve that change the procedure approach for physicians. And better for the patients. Obviously, we embrace that. But we've been able to backfill with other services, expand our markets, get into new capabilities, and ultimately keep the company moving forward in the face of those incremental changes that occur. And that's what I think is unique in many respects to our platform, the services we provide, and how we approach our business.
多年來,我們看到新技術演進,改變了醫師的手術處置方式。而且對病患更好。顯然,我們擁抱這些變化。但我們也能以其他服務來補位、擴展我們的市場、發展新的能力,並最終在面對這些逐步發生的變化時,持續推動公司向前。而我認為,這在許多方面是我們平台、我們提供的服務,以及我們經營方式的獨特之處。
It gives us the diversification in some regards that allows us to navigate through these incremental issues that surface from time to time.
在某些方面,這也帶來多元化,使我們能夠穿越這些不時浮現的漸進式問題。
Operator
Operator
Craig Hettenbach, Morgan Stanley.
Craig Hettenbach,摩根士丹利。
Craig Hettenbach - Analyst
Craig Hettenbach - Analyst
Yes, thank you. Mike, the comment that resiliency is part of the core now, can you just touch on some of the applications you've been able to accelerate this year, as well as any untapped opportunities you see on a longer-term basis on resiliency?
是的,謝謝。Mike,你提到韌性現在已是核心的一部分,你能否談談今年你們加速推進的一些應用,以及從更長期角度來看,在韌性方面你們看到的任何尚未開發的機會?
Michael Marks - Chief Financial Officer, Executive Vice President
Michael Marks - Chief Financial Officer, Executive Vice President
When we think about resiliency, we largely think about four key focus areas that really make up this multifaceted effort across the enterprise.
當我們思考韌性時,我們主要聚焦在四個關鍵重點領域,這些領域構成了全企業多面向的努力。
The first one is really revenue integrity and working to ensure that we collect the revenue for the services we provide under the contracts that we operate.
第一個是營收完整性(revenue integrity),並致力於確保我們依據所執行的合約,能夠收取我們所提供服務的營收。
That's number one. Number two is asset optimization, Craig, and that's important. That's that patient flow that Sam was talking about. And certainly, that's important on the inpatient side. It's also important in our emergency rooms, our operating rooms, our cath labs. And so we continue to see good performance on patient flow and there's a lot of opportunity ahead. We are nowhere near the back innings here on asset optimization and feel good about the work ahead there.
這是第一點。第二點是資產最佳化(asset optimization),Craig,這很重要。這就是 Sam 所談到的病患流動(patient flow)。而且這在住院端當然很重要。在我們的急診室、手術室、心導管室(cath labs)也同樣重要。因此,我們持續看到病患流動有良好表現,而且未來仍有很大的機會。在資產最佳化方面,我們離後段局數還差得遠,對接下來要做的工作很有信心。
Third is variable cost, things like labor, supplies and even some of our variable operating costs, which are performing well this year. We have a number of resiliency plans that are driven to focus on.
第三是變動成本(variable cost),例如人力、耗材,甚至部分變動性的營運成本;這些今年表現良好。我們有多項韌性計畫,都是以聚焦於……為導向。
Variable cost. And when we look ahead, we continue to see opportunity and the variability across the company in our benchmarking tools and advanced analytics and taking that forward. And then lastly are fixed costs, both at corporate and in the field, which are an important part here.
變動成本。展望未來,透過我們的標竿比較工具與進階分析,我們持續看到機會,以及公司內部在各項指標上的差異性,並將其推進落地。最後則是固定成本(fixed costs),包含總部與各地營運端,這也是其中重要的一環。
So as I think about where we are today, we have good resiliency efforts that have been in our past and that are certainly improving our current year's performance. We have a great line of sight now going into 2027 and into 2028 and beyond.
所以就我看我們目前的位置而言,我們過去就有良好的韌性努力,且確實正在改善今年的表現。我們現在對 2027 年、2028 年及更長遠的未來,都有非常清晰的能見度。
And I think about things like the digital transformation is really being a key enabler that gives us that confidence that we're going to have resiliency benefits in the years to follow.
而我想到像是數位轉型,確實是關鍵的賦能因素,讓我們有信心在未來幾年持續獲得韌性帶來的效益。
We continue to build out our global capabilities.
我們也持續擴建我們的全球能力。
I think about the underlying work of expanding our shared service platforms. We have a number of expansions in flight where, for example, Parallon is taking on additional administrative functions for the company and bringing shared service scale and expertise to broader parts of our work. So as I sit here today at the end of the third quarter of '26, we believe that we're in a really good spot. We have. Multi-year, multifaceted enterprise-wide approach to resiliency, and we believe it's going to produce great results as we move forward.
我也想到擴大我們共享服務平台的基礎工作。我們有多項擴張正在進行中;例如,Parallon 正在承接公司更多的行政職能,並把共享服務的規模與專業帶到我們工作中更廣泛的領域。因此,當我在 2026 年第三季末坐在這裡時,我們相信我們處於非常好的位置。我們有。一個多年期、多面向、全企業範圍的韌性策略,我們相信它將在我們持續前進時產生很好的成果。
Frank Morgan - Vice President, Investor Relations
Frank Morgan - Vice President, Investor Relations
Christine, I think we're at the end of our allotted time for questions.
Christine,我想我們已經到達分配給提問的時間尾聲了。
Operator
Operator
We have reached the end of the Q&A session. I will now turn the call back to Frank for closing remarks.
問答環節已結束。我現在把電話會議交回 Frank 作結語。
Frank Morgan - Vice President, Investor Relations
Frank Morgan - Vice President, Investor Relations
Christine, thank you for your help today on the call and thanks to everyone for joining us. Please reach out to me if you have any additional questions.
Christine,謝謝你今天在電話會議中的協助,也感謝各位的參與。如果你有任何其他問題,請與我聯繫。
Thank you very much.
非常感謝。
Operator
Operator
This concludes today's call.
今天的電話會議到此結束。
Thank you for attending. You may now disconnect.
感謝各位出席。您現在可以掛線。